Project Grant R03AI190490
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant of $670,017 under the Allergy and Infectious Diseases Research program (CFDA 93.855) with an award date of February 4, 2026, and completion date of January 31, 2031. This five-year research initiative investigates the regulatory mechanisms by which the E3 ubiquitin ligase CUL5 (Cullin-5) restrains cytokine signaling in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Ann & Robert H Lurie Children's Hospital of Chicago a $1,530,922 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 10, 2025, for the refinement and validation of a symptom report-based food allergy (FA) prevalence questionnaire for population-based studies. The project, extending through August 31, 2029, addresses the critical gap in...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $493,889 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective April 1, 2026, through March 31, 2031. This award supports investigator-initiated biomedical research aimed at elucidating the mechanisms underlying food-specific immunoglobulin E (IgE) antibody induction in the gastrointestinal...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $106,922 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 26, 2026, with completion targeted for October 31, 2028. The award supports investigator-initiated biomedical research examining the pathogenic mechanisms underlying food allergen absorption and anaphylaxis risk....
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $522,524 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, with a completion date of June 30, 2030. This award supports research into the mechanism of inflammation in adenosine deaminase 2 (ADA2) deficiency (DADA2), a rare inborn error of immunity characterized by systemic inflammation, vascular involvement,...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant totaling $3,375,359 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 9, 2025. The four-year research initiative, with anticipated completion by June 30, 2029, will deliver scientific research focused on understanding the mechanisms of epithelial reprogramming and barrier dysfunction in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Michigan a $250,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 21, 2025, with a completion date of July 31, 2026. The award supports the development of a novel synthetic immunological niche (IN) scaffold technology designed to analyze and predict immune response heterogeneity in food allergies. The research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Children's Hospital of Philadelphia $881,303 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 17, 2025, for a project extending through June 30, 2030. This Project Grant funds a comprehensive research initiative utilizing whole genome sequencing (WGS) and diagnostic allele (DA) surveillance to track pathogen transmission and infection dynamics in neonatal...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $800,557 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 19, 2026, with a completion date of January 31, 2031. This research initiative focuses on identifying mechanisms by which the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The project addresses a...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $122,472 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Children's Hospital on August 13, 2025, with a completion date of July 31, 2027. This award supports investigator-initiated research aimed at elucidating the molecular mechanisms underlying the activation and regulation of the NLRP3 inflammasome, a critical component of the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Children's Research Institute a $182,000 Project Grant (R03 award) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. This research project will generate empirical findings on caregiver beliefs, perceived treatment benefits and burdens, and psychosocial functioning related to Xolair (omalizumab) food allergy treatment for children. Specifically, the research will identify food allergy beliefs among caregivers of children pursuing Xolair treatment and determine the relationship between treatment uptake and caregivers' psychosocial outcomes, addressing a gap in clinical trial data that did not assess impacts on caregiver fear and food allergy anxiety—critical factors influencing treatment decisions. This award addresses a significant public health need, as food allergy affects up to 8% of children in the United States, with caregivers consistently reporting intense fear regarding life-threatening anaphylaxis. The research will provide evidence to inform shared decision-making between families and allergy care providers regarding this newly FDA-approved treatment option, thereby supporting improved clinical outcomes and informed treatment adoption among affected pediatric populations.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $182.0k | 4/1/26 |